---
search:
  boost: 3
---

# Tetracyclines

This is a subcategory of Infectious Disease Agents.

## Formulary

### Preferred

| Preferred                     | Generic Name | Quantity | Time (Days) |
| :---------------------------- | :----------- | :------: | :---------: |
| Doxycycline 50, 100 MG        |              |          |             |
| Doxycycline Syr <sup>AR</sup> |              |          |             |
| Minocycline Cap               |              |          |             |
| Tetracycline                  |              |          |             |
| Vibramycin Susp <sup>AR</sup> |              |          |             |

### Non-Preferred

| Non-Preferred                  | Generic Name | Quantity | Time (Days) |
| :----------------------------- | :----------- | :------: | :---------: |
| Demeclocycline                 |              |          |             |
| Doxycycline 20, 40, 75, 150 MG |              |          |             |
| Doxycycline DR                 |              |          |             |
| Minocycline IR, ER Tab         |              |          |             |
| Nuzyra                         |              |          |             |

## Authorizations

**Length of Authorizations**: Based on indication for acute infections or 365 days for acne

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **3 days** with at least **one preferred** drug for acute infections **OR** at least **90 days** with at least **one preferred oral** drug for acne
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Additional Information

- Requests may be authorized if:
    - The infection is caused by an organism resistant to ALL preferred antibiotics (must provide diagnosis and any culture/sensitivity results)
    - The patient is completing a course of therapy that was started in the hospital or other similar location or was started before Medicaid eligibility, only the remaining course will be authorized

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring, **AND** medical necessity for continued use

**AR** - Vibramycin Suspension: a PA is required for patients 12 years and older 

**AR** - Doxycycline Syrup: a PA is required for patients 12 years and older

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_Criteria%20_APPROVED.pdf#page=80){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_v7_Approved.pdf#page=26){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
